LivaNova PLC (LIVN) · Aug 5, 2026 · Company update

Guidance rises after broad beat, though cash outlook retreats

Guidance rises after broad beat, though cash outlook retreats

The quarter cleared published expectations on both sales and core earnings. Revenue of $390.6 million exceeded the published consensus of about $380.5 million by roughly $10 million, while adjusted diluted EPS of $1.26 was $0.17 above the published $1.09 expectation. Growth was not solely currency-driven: revenue rose 9.8% at constant currency, with Cardiopulmonary up 9.9% and Neuromodulation up 9.5%. (Net Revenue table; GAAP-to-Non-GAAP reconciliation)

MetricQ2 2026Q2 2025Expectation / prior outlook
Revenue$390.6M$352.5MPublished consensus: ~$380.5M (Net Revenue table)
Constant-currency revenue growth9.8%—— (Financial Highlights)
Adjusted diluted EPS$1.26$1.05Published consensus: ~$1.09 (GAAP-to-Non-GAAP reconciliation)
Adjusted operating margin23.2%21.9%— (GAAP-to-Non-GAAP reconciliation)
FY 2026 constant-currency revenue growth guide8%–9%—Prior: 7%–8% (2026 Outlook)
FY 2026 adjusted diluted EPS guide$4.30–$4.40—Prior: $4.20–$4.30 (2026 Outlook)
FY 2026 adjusted free-cash-flow guide$140M–$160M—Prior: $160M–$180M (2026 Outlook)

The outlook increase turns a one-quarter beat into a higher full-year baseline. Management lifted the midpoint of constant-currency revenue growth by 100 basis points and adjusted EPS by $0.10, rather than simply reiterating prior targets. First-half constant-currency revenue growth was already 10.4%, above the newly raised full-year range, while both major businesses grew at roughly 10% in the quarter. (Six-Month Net Revenue table; 2026 Outlook)

The eye-catching GAAP EPS is mostly a tax-event effect, not the operating result to extrapolate. GAAP diluted EPS reached $1.93, but the reconciliation shows a $1.97-per-share tax adjustment tied to the favorable Italian ruling on deductibility of the SNIA environmental liability; adjusted EPS was $1.26. Core profitability did improve—adjusted operating income rose to $90.8 million from $77.4 million and adjusted operating margin expanded 130 basis points—but GAAP operating income fell to $49.5 million from $54.2 million amid $12.4 million of other operating expense. (Income Statement; GAAP-to-Non-GAAP reconciliation; Tax Adjustment reconciliation)

The meaningful offset is lower cash generation, not weaker revenue or profit guidance. The adjusted free-cash-flow midpoint fell $20 million to $150 million as the company accelerates Cardiopulmonary capacity, innovation and IT investment. That spending may support future demand fulfillment—alongside the new oxygenator-component supply agreement—but it means the improved sales and EPS outlook requires more near-term cash investment. (2026 Outlook; Cash Flow statement)

Original filing on SEC EDGAR

More LivaNova PLC news

Guidance rises after broad beat, though cash outlook retreats | LIVN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.